Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1Phase 1/2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Classical hematology 2Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

fostamatinib 3romiplostim 2eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Purpura, Thrombocytopenic, Idiopathic × Clear all
NCT02077192 2023-12-11

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

Phase 3 Completed
123 enrolled 11 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT01957176 2022-12-30

A Rollover Study to Provide Continued Treatment With Eltrombopag

Novartis

Phase 4 Completed
22 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myeloid, Acute, Purpura, Thrombocytopenic, Idiopathic

NCT02076399 2019-02-12

FIT

Rigel Pharmaceuticals

Phase 3 Completed
76 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076412 2019-01-25

FIT

Rigel Pharmaceuticals

Phase 3 Completed
74 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Amgen

Phase 1/2 Completed
22 enrolled 13 charts 1 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡